Research from University College London (UCL) reveals that smoking significantly reduces life expectancy – by 17 minutes per cigarette for men and 22 minutes for women. Women, in particular, face higher risks due to hormonal factors and are more vulnerable to diseases like lung cancer and cardiovascular conditions. In Pakistan, smoking continues to pose a major public health challenge, with an estimated 31 million people affected. The consequences are dire – smoking is responsible for over 160,000 deaths annually.
A recent ruling by the U.S. Food and Drug Administration (FDA) presents a potential way forward for Pakistan. The FDA has authorized the marketing of ZYN oral nicotine pouches as a better alternative to smoking. Unlike smoking, these pouches deliver nicotine without combustion, thus eliminating the harmful effects of tar and carbon monoxide. Despite widespread awareness of these risks, many smokers find it difficult to quit due to nicotine dependence, social factors, and stress. For these individuals, access to reduced-risk alternatives could be transformative.
While the U.S. is advancing harm reduction strategies through regulation and oversight, Pakistan remains significantly behind in implementing similar measures. Nicotine pouches are available in the local market but exist in a regulatory gray area. Without clear guidelines, public health authorities cannot effectively monitor product quality, safety, or marketing practices, potentially exposing consumers to unregulated products.
Regulating nicotine pouches could be a crucial step toward reducing smoking prevalence in Pakistan. By establishing a robust regulatory framework, Pakistan can ensure that nicotine pouches meet safety standards, are appropriately labeled, and are accessible to adult smokers seeking alternatives.
For Pakistan, the question is no longer whether such alternatives should be available, but how they can be effectively regulated to safeguard public well-being.
